GTS Securities’s Boston Scientific BSX Stock Holding History

GTS Securities’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-16,000	Closed	-$1.34M	–	1632
2024 Q3	$1.34M	Sell	16,000 -1,900	-11%	-$150K	﹤0.01%	1893
2024 Q2	$1.38M	Buy	17,900 +10,900	+156%	+$798K	﹤0.01%	1788
2024 Q1	$479K	Buy	+7,000	New	+$450K	﹤0.01%	2617
2023 Q4	–	Sell	-15,500	Closed	-$818K	–	4058
2023 Q3	$818K	Buy	+15,500	New	+$813K	﹤0.01%	2179

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

GTS Securities's BSX Position: Q2 2026 in Review

GTS Securities sold out of Boston Scientific (BSX) in Q2 2026, closing a stake of 6,962 shares — an estimated $437K sold.

GTS Securities first reported a position in BSX in Q3 2023 and held it in 10 quarters. The position peaked at $6.86M in Q3 2024. 1,482 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

GTS Securities reported no remaining Boston Scientific position as of Q2 2026 after selling out during the quarter.
GTS Securities sold 6,962 Boston Scientific shares in Q2 2026, an estimated $437K.
GTS Securities first reported a position in Boston Scientific in Q3 2023 and held it in 10 quarters.
GTS Securities's Boston Scientific position peaked at $6.86M in Q3 2024.
1,482 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.